Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Out of Compliance with Nasdaq Listing Requirement

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics is out of compliance with a Nasdaq listing requirement, the firm said in a document filed with the US Securities and Exchange Commission on Friday.

The company said that it was notified by Nasdaq on July 31 that the market value of its listed securities did not meet the exchange's minimum standard of at least $35 million for the past 30 consecutive trading days. HTG has until Jan. 29, 2018 to regain compliance by meeting the $35 million requirement for at least 10 consecutive business days.

If the firm cannot regain compliance between then, it will receive a delisting determination from Nasdaq. HTG would be able to appeal the determination to a Nasdaq Hearings Panel, the company said.

Shares of HTG closed at $2.24 on Friday. Its market value was $21.3 million based on 9.53 million shares outstanding. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.